Rinat Bernstein-Molho

Suggest Changes
Learn More
OBJECTIVE This study reports the efficacy and safety of zoledronic acid (ZOL) in preventing bone loss in postmenopausal patients receiving an aromatase inhibitor (AI) following tamoxifen. METHODS(More)
e11111 Background: Adjuvant treatment with aromatase inhibitors (AIs) in postmenopausal women (PMW) with early breast cancer (EBC) can be associated with bone loss. Update of BIG-98 suggests that(More)
  • 1